Inhaled genetic therapy for cystic fibrosis patients
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests an inhaled medicine that delivers a corrective genetic message (mRNA) to lung cells in people with cystic fibrosis. It aims to see if the treatment is safe and can improve lung function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You must have a confirmed cystic fibrosis diagnosis and be in stable health.
- You need a minimum weight (40 kg for adults, 30 kg for teens).
- Your lung function must be at least 40% of normal, and your oxygen level at rest at least 92%.
- You must have quit smoking for at least 2 years.
- No recent lung infections, significant coughing up blood, or changes in CF medications within the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
This study looks at correcting “stop” mistakes (nonsense mutations) in the CFTR gene, which can cause cystic fibrosis. If your CFTR test shows the exact type of mutation the study needs, you may be able to take part.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This Phase 1 study tests the safety of KB407 and how it works in adults with cystic fibrosis (CF). It may help researchers understand whether this inhaled treatment could become a future option for CF.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.